BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26824771)

  • 1. Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.
    Naber SK; Matthijsse SM; Rozemeijer K; Penning C; de Kok IM; van Ballegooijen M
    PLoS One; 2016; 11(1):e0145548. PubMed ID: 26824771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better?
    Sander B; Wong WW; Yeung MW; Ormanidhi O; Atkin K; Murphy J; Krahn M; Deeks SL
    Vaccine; 2016 Apr; 34(16):1936-44. PubMed ID: 26892739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
    Kim JJ; Ortendahl J; Goldie SJ
    Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
    Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
    BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
    Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
    J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
    Anonychuk AM; Bauch CT; Merid MF; Van Kriekinge G; Demarteau N
    BMC Public Health; 2009 Oct; 9():401. PubMed ID: 19878578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Kaló Z
    BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Pedersen K; Portnoy A; Sy S; Hansen BT; Tropé A; Kim JJ; Burger EA
    Int J Cancer; 2022 Feb; 150(3):491-501. PubMed ID: 34664271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.